RESULTS. Participants with CAD ( n = 723) had 12% higher mean relative levels of nHDL ox compared with those with invasively excluded CAD ( n = 502, P < 0.001). Patients presenting with symptoms of an ACS had the highest nHDL ox values when compared with the elective cohort (median 1.35, IQR 0.97 to 1.85, P < 0.001). In multivariate analysis adjusted for age, sex, body mass index, and hypertension, nHDL ox was a strong independent predictor of ACS ( P < 0.001) but not of CAD ( P > 0.05).CONCLUSION. HDL antioxidant function is reduced in patients with CAD. nHDL ox is strongly associated with ACS. TRIAL REGISTRATION. German Clinical Trials Register DRKS00014037. FUNDING. Brandenburg Medical School Theodor Fontane, the BIOX Stiftung, and NIH grants R01AG059501 and R03AG059462. BACKGROUND. High-density lipoprotein (HDL) function rather than its concentration plays an important role in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to determine whether reduced antioxidant function of HDL is associated with the presence of a stable CAD or acute coronary syndrome (ACS).METHODS. HDL function was measured in 2 cohorts: 1225 patients admitted electively for coronary angiography and 196 patients with ACS. A validated cell-free biochemical assay was used to determine reduced HDL antioxidant function, as assessed by increased HDL-lipid peroxide content (HDL ox ), which was normalized by HDL-C levels and the mean value of a pooled serum control from healthy participants (nHDL ox ; unitless). Results are expressed as median with interquartile range (IQR).
Background: Patients who have undergone prior pulmonary vein isolation (PVI) for atrial fibrillation (AF) often require a repeat ablation for AF recurrence. The optimal ablative strategy for the redo procedure and predictors of AF recurrence thereafter remain largely unknown. Purpose: We aimed to characterise the ablation strategies applied at re-PVI and identify possible predictors of AF recurrence. Methods: Our single-centre, retrospective study included all consecutive patients who underwent first redo PVI at our centre from 2017 to 2022. Inclusion criteria required at least one available follow-up visit within the first 12 months after the redo procedure. Ablation strategies of the initial and redo procedure were captured. Kaplan-Meier curves were used to illustrate time of AF recurrence, as classified by predictors of outcome determined by multivariable regression analyses. Results: We included 215 patients (39.1% female) with a median age of 66.6 years (IQR 58.6-73.2) at the time of redo procedure. The initial PVI was cryoablation in 39.9%, RFA in 57.7% and surgical ablation in 2.4%. After the initial procedure, 55.8% had paroxysmal AF and 44.2% had persistent AF. At the redo procedure, 25.1% of patients were found to have no PV reconnection, whereas 20.5% had a single reconnected PV, and 54.4% had two or more reconnected PVs. A left-sided flutter ablation was performed in 18.8%, a left atrial (LA) roof line in 16.9%, a posterior mitral isthmus line in 5.2%, an anterior mitral isthmus line in 27.9%, and a posterior box lesion in 8.4%. Overall, 34.4% of patients showed areas of low-voltages in the redo procedure. Patients with areas of low voltages were less likely to have any reconnected PVs in the redo-procedure (p<0.001). After the second ablation procedure, 54.0% experienced AF recurrence. Univariable regression analysis revealed moderate (p=0.006) or severe (p= 0.015) LA dilatation, persistent AF (p=0.005), and posterior LA low voltage areas (p=0.011) as significant predictors of AF recurrence after the redo procedure. The number of reconnected PVs at the re-PVI did not predict AF recurrence (p=0.1090). As illustrated in Fig. 1 and 2, patients with paroxysmal AF experienced less AF recurrence compared to those with persistent AF (log-rank p=0.0025). Moreover, moderate or severe LA dilatation at baseline was associated with more frequent AF recurrences (log-rank p=0.0279). Conclusion: A significant proportion of patients undergoing re-PVI experienced AF recurrence. We found that persistent AF and moderate or severe LA enlargement emerged as significant predictors of AF recurrence after the redo procedure. Although PV reconnection was observed in more than two thirds of patients at the re-PVI, it did not predict AF recurrence thereafter. However, patients without PV reconnection had significantly more low-voltage areas, which may be indicative of a different AF recurrence mechanism in this subgroup.Figure 1:Type of AFFigure 2:LA dilatation
Background: Obesity, commonly defined by body mass index (BMI), promotes cardiovascular disease through chronic inflammation and oxidative stress, which impair high-density lipoprotein (HDL) function and favor oxidative modification. Oxidized HDL (HDLox) may link adiposity to cardiovascular risk. However, the association between BMI and HDLox across the adiposity spectrum remains unclear. We therefore examined this relationship in a Coronary-Suspected Cohort. Methods: This study included 1,227 consecutive patients undergoing elective coronary angiography. Participants were stratified into five predefined BMI categories. HDLox was quantified using a validated fluorometric assay assessing HDL lipid peroxide content. Associations between BMI and HDLox were analyzed using univariable and multivariable linear regression across the full BMI range and within a restricted BMI interval (15–35 kg/m²). Results: HDLox levels were significantly higher in overweight and obese individuals compared with normal-weight participants (p = 0.002 and p < 0.001). HDLox increased from normal weight to obesity class I (BMI 30–34.9 kg/m²) and plateaued at higher BMI levels, indicating a non-linear relationship. In the overall cohort, BMI showed a weak but significant association with HDLox (β = 0.064, p = 0.024). Within the restricted BMI interval, the association was more pronounced (β = 0.158, p < 0.001). In multivariable models, BMI, high-sensitivity C-reactive protein, and male sex remained independently associated with HDLox, whereas traditional cardiovascular risk factors were not. Conclusions: HDL oxidation increases early during weight gain and may represent a functional marker linking adiposity-related inflammation and oxidative stress to cardiovascular vulnerability.
Obesity, commonly defined by body mass index (BMI), promotes cardiovascular disease through chronic inflammation and oxidative stress, which impair high-density lipoprotein (HDL) function and favor oxidative modification. Oxidized HDL (HDLox) may link adiposity to cardiovascular risk. However, the association between BMI and HDLox across the adiposity spectrum remains unclear. We therefore examined this relationship in a Coronary-Suspected Cohort. This study included 1227 consecutive patients undergoing elective coronary angiography. Participants were stratified into five predefined BMI categories. HDLox was quantified using a validated fluorometric assay assessing HDL lipid peroxide content. Associations between BMI and HDLox were analyzed using univariable and multivariable linear regression across the full BMI range and within a restricted BMI interval (15–35 kg/m2). HDLox levels were significantly higher in overweight and obese individuals compared with normal-weight participants (p = 0.002 and p < 0.001). HDLox increased from normal weight to obesity class I (BMI 30–34.9 kg/m2) and plateaued at higher BMI levels, indicating a non-linear relationship. In the overall cohort, BMI showed a weak but significant association with HDLox (β = 0.064, p = 0.024). Within the restricted BMI interval, the association was more pronounced (β = 0.158, p < 0.001). In multivariable models, BMI, high-sensitivity C-reactive protein, and male sex remained independently associated with HDLox, whereas traditional cardiovascular risk factors were not. HDL oxidation increases early during weight gain and may represent a functional marker linking adiposity-related inflammation and oxidative stress to cardiovascular vulnerability.